Introduction: Previous studies in patients with irreversible pulpitis have reported increased success of the inferior alveolar nerve block (IANB) using premedication with ketorolac. Preemptive nitrous oxide administration has also shown an increase in the success of the IANB. Recently, ketorolac has been made available for intranasal delivery. Perhaps combining ketorolac and nitrous oxide would increase success. Therefore, the purpose of this prospective, randomized, double-blind study was to determine the effect of a combination of intranasal ketorolac and nitrous oxide/oxygen on the anesthetic success of the IANB in patients presenting with symptomatic irreversible pulpitis. Methods: One hundred two patients experiencing spontaneous moderate to severe pain with symptomatic irreversible pulpitis in a mandibular posterior tooth participated. Patients were randomly divided into 2 groups and received either 31.5 mg intranasal ketorolac or intranasal saline placebo 20 minutes before the administration of nitrous oxide/oxygen. Ten minutes after the administration of nitrous oxide/oxygen, the IANB was given. After profound lip numbness, endodontic treatment was performed. Success was defined as the ability to perform endodontic access and instrumentation with no pain or mild pain. Results: The odds of success for the IANB was 1.631 in the intranasal saline/nitrous oxide group versus the intranasal ketorolac/nitrous oxide group with no significant difference between the groups (P = .2523). Conclusions: Premedication with intranasal ketorolac did not significantly increase the odds of success for the IANB over the use of nitrous oxide/oxygen alone. Supplemental anesthesia will still be needed to achieve adequate anesthesia. (J Endod 2018;44:9-13) 
T he inferior alveolar nerve block (IANB) does not always result in successful pulpal anesthesia (1) . The overall success rate (defined as no or mild pain upon endodontic access) for an IANB in patients presenting with symptomatic irreversible pulpitis ranges from 15%-57% (1). Fowler et al (2) evaluated success in molars and premolars in patients with symptomatic irreversible pulpitis. They found the IANB success rate was 28% for first molars, 25% for second molars, and 39% for premolars, with no significant differences when comparing molars with premolars.
Studies have attempted to increase the success of the IANB through buffering, varying anesthetics and dosing, the use of the Gow-Gates and Vazirani-Akinosi techniques, and preoperative medications (1) . Generally, the results have not proven to be completely effective (1) . One method that has shown increased success is the administration of nitrous oxide. Stanley et al (3) , in mandibular teeth diagnosed with symptomatic irreversible pulpitis, found the administration of 30%-50% nitrous oxide resulted in a statistically significant increase in the success (50%) of the IANB versus 28% without nitrous oxide. However, the increase was not high enough to ensure clinical success without the use of supplemental anesthesia.
Studies in endodontics have focused on the use of ketorolac for pain reduction (4), using it as an oral premedication (5) (6) (7) (8) or as a buccal infiltration (9, 10) to increase the success of the IANB. Although some studies have shown an improved effect (6-10), Aggarwal et al (5) did not. A review by Li et al (11) called for more studies to evaluate preemptive nonsteroidal anti-inflammatory drugs (NSAIDs) and their impact on IANB success.
Ketorolac is indicated for the management of moderate to severe pain (12) . Ketorolac and other nonselective NSAIDs exert their analgesic, anti-inflammatory, and antipyretic effects through the inhibition of cyclooxygenase (12) . Because ketorolac is more selective for cyclooxygenase 1, which is found in the central nervous system, it may be possible that ketorolac has central analgesic activity that ibuprofen does not possess (12) . Ketorolac has a good safety profile (13, 14) . Ketorolac has traditionally been administered via intramuscular or intravenous routes.
Recently, ketorolac has been made available as an intranasal spray (Sprix; Regency Therapeutics, Shirley, NY). Sprix has been shown to decrease postoperative pain in oral surgery (15, 16) and medical models (17) (18) (19) (20) .
In dentistry, most drugs are administered orally, which has the disadvantages of decreased absorption rates and delayed onset. The intranasal administration of ketorolac was rapidly absorbed, exhibited a maximum plasma concentration within 30 to 45 minutes of administration, and had a half-life of 5 to 6 hours (13, 14) . McAleer et al (13) concluded that 30 mg intranasal ketorolac was equivalent to approximately 20 mg intramuscular ketorolac. Intranasal drug delivery is an attractive option because of the ease of administration, rapid onset of action, avoidance of gastrointestinal and hepatic first-pass effects, and the nasal mucosa's high permeability and rich vascularity (21) . Intranasal drugs are primarily absorbed in the inferior turbinate because of its vascularity and large surface area (21) . However, because of the limited space in the nasal cavity, the volume of drug administered should be less than 200 mL total or, in other words, 100 mL in each nostril (21) . This volume correlates to the manufacturer's recommended dose of 1 spray in each nostril (100 mL), with each containing 15.75 mg ketorolac tromethamine. The intranasal route of administration may be more effective than traditional oral delivery.
Although increased success of the IANB has been shown for both nitrous oxide and ketorolac individually, neither has shown success rates that would ensure clinical success without the use of supplemental anesthesia. Perhaps the combination of the 2 medications with varying mechanisms of action would improve overall success and reduce intraoperative pain for patients. No study has investigated the efficacy of a combination of intranasal ketorolac and nitrous oxide/oxygen for increasing the success of the IANB in patients diagnosed with symptomatic irreversible pulpitis. Therefore, the purpose of this prospective, randomized, double-blind study was to determine the effect of a combination of intranasal ketorolac and nitrous oxide/oxygen on the anesthetic success of the IANB in patients presenting with symptomatic irreversible pulpitis.
Materials and Methods
One hundred two adult patients participated in this study. All were emergency patients and in good health as determined by a health history and oral questioning. Exclusion criteria were as follows: under 18 or over 64 years of age; less than 110 lb in weight; allergy to nitrous oxide or ketorolac; history of significant medical problem (American Society of Anesthesiologists classification III or greater); taking pentoxifylline or probenecid, kidney disease, bleeding disorder, stomach ulcer, heart disease, angioedema, or bronchospastic reactivity to aspirin or other NSAIDS; depression, schizophrenia, or bipolar disorder; nasopharyngeal obstructions, respiratory infection, or sinusitis; recently took central nervous system depressants (including alcohol or any analgesic medications); pregnancy; lactating; or the inability to give informed consent. The Ohio State University Human Subjects Review Committee approved the study, and written informed consent was obtained from each patient.
Each patient had a vital mandibular posterior tooth (molar or premolar) with a clinical diagnosis of symptomatic irreversible pulpitis, was actively experiencing pain, and had a prolonged response to cold testing with Endo-Ice (1,1,1,2 tetrafluoroethane; Hygenic Corp, Akron, OH). Patients with no response to cold testing, periradicular pathosis (other than a widened periodontal ligament), or no vital coronal pulp tissue upon access were excluded from the study.
We included posterior teeth to evaluate the teeth that would commonly require endodontic treatment and that have the most difficulty achieving profound anesthesia (1) . A study by Fowler et al (2) showed that the success rates of the IANB in patients with symptomatic irreversible pulpitis for first molars, second molars, and premolars were not significantly different. Therefore, based on this evidencebased research, using posterior teeth is acceptable when evaluating the IANB.
Each patient rated his or her initial pain on a Heft-Parker 170-mm visual analog scale (VAS) (22) . The VAS was divided into 4 categories. No pain corresponded to 0 mm. Mild pain was defined as greater than 0 mm and less than or equal to 54 mm. Mild pain included the descriptors of faint, weak, and mild pain. Moderate pain was defined as greater than 54 mm and less than 114 mm. Severe pain was defined as equal to or greater than 114 mm. Severe pain included the descriptors of strong, intense, and maximum possible. Patients had to present with spontaneous moderate to severe initial pain to be included in the study.
The 2 treatments (intranasal ketorolac or intranasal saline placebo) were assigned random 6-digit numbers. Each patient was assigned a 6-digit random number to determine which treatment regimen would be administered. Only the random numbers were recorded on the data collection sheets to maintain blinding of the experiment.
The patients randomly received either 31.5 mg intranasal ketorolac (Sprix) (1 spray of 15.75 mg ketorolac tromethamine per nostril) or intranasal bacteriostatic 0.9% sodium chloride (1 spray per nostril using a similar-sized spray bottle as Sprix made by Central Ohio Compounding, Columbus, OH) 30 minutes before the IANB.
A trained research assistant not involved in the IANB injections or endodontic access administered either intranasal ketorolac or intranasal saline. The principal investigator (D.S.) was not present in the operatory, did not see either spray bottle, and was not involved with the administration of the medication or the saline placebo. The patients were informed that intranasal ketorolac or saline was to be administered by dispensing 1 spray in each nostril. This followed the instructions provided by the Sprix manufacturer (23) . The patients were instructed to gently blow their nose before the administration of the nasal spray and advised that during administration they were not to inhale. The patients were then instructed to tilt their head slightly forward and deposit 1 spray into each nostril with the tip of the bottle facing away from the center of their nose. The patients reported any sensations/side effects (eg, burning or tingling) during administration of the medication or placebo.
The nitrous oxide/oxygen was administered 10 minutes before the IANB (20 minutes after intranasal ketorolac or intranasal saline) with a scented nasal mask (Accutron, Inc, Phoenix, AZ) and a nitrous oxide machine (McKesson Equipment Company, Chesterfield, UK). A 6-L/ min flow rate of 100% oxygen was established, and the patient adjusted the nasal hood for comfort. Patients were instructed to breathe through their nose. After 5 minutes of 100% oxygen, the nitrous oxide/oxygen was titrated until an ideal sedation level was reached at a 30%-50% concentration. The patient was maintained at this level for 5 minutes before the injection of local anesthetic.
An IANB was administered 15 minutes before endodontic access (10 minutes after nitrous oxide/oxygen administration and 30 minutes after intranasal ketorolac or saline) with 3.6 mL 2% lidocaine with 1:100,000 epinephrine (Xylocaine; AstraZeneca LP, Dentsply, York, PA) using a conventional IANB (24) 
The patient was questioned every minute for 15 minutes after the IANB to see if his or her lip was numb. If profound lip numbness was not recorded at 15 minutes, the block was considered missed, and the patient was excluded from the study. No patients were excluded for a lack of lip numbness. Once profound lip numbness was achieved, the patients with molar teeth were given a buccal nerve block using 0.4 mL 2% lidocaine with 1:100,000 epinephrine for rubber dam clamp anesthesia.
At 15 minutes after the IANB (45 minutes after intranasal administration and 25 minutes after nitrous oxide administration), the tooth was isolated with a rubber dam, and endodontic access was performed. Endodontic debridement was performed using 3% sodium hypochlorite irrigation, stainless steel K-type files (Dentsply International, Inc, Johnson City, TN), and rotary files (Vortex, Dentsply International, Inc, Johnson City, TN). The working length was determined using periapical digital radiographs that were confirmed with an apex locator (Root ZX II; Morita USA, Irvine, CA). The canals were prepared to a minimum size of 30/.04 or 40/.04 depending on the tooth and canals treated. Patients were instructed to definitively rate any pain felt during endodontic access and debridement. If the patient felt pain, the treatment was immediately stopped, and the patient rated his or her discomfort using the Heft-Parker VAS. If the pain rating was mild, treatment continued. If the pain rating was moderate or greater (55 mm or higher on the VAS), supplemental anesthesia was administered (buccal infiltration of articaine and/or intraosseous injections). The extent of access achieved when the patient felt pain was recorded as within dentin, entering the pulp chamber, or file placement. The success of the IANB was defined as the ability to access and instrument the tooth without pain (VAS score of 0) or with mild pain (VAS rating less than or equal to 54 mm). The principal investigator (D.S.) administered the nitrous oxide and the IANB and performed the endodontic treatment.
After the endodontic treatment, the patient remained on 100% oxygen for at least 5 minutes. The patient was dismissed unescorted when it was determined that he or she had completely recovered from the sedation.
Patients rated the degree of satisfaction with the endodontic treatment using a 100-mm analog scale for assessing satisfaction as was described previously (3, 25) . The ratings were completed at the end of the appointment after the principal investigator left the operatory. The satisfaction survey was given to the front desk receptionist when making the appointment for the completion of the endodontic treatment. It was emphasized that the satisfaction survey would not affect the principal investigator's grades or standing in the residency so that patients were encouraged to be honest in their assessment.
The data were analyzed statistically. Comparisons between the intranasal ketorolac/nitrous oxide and intranasal saline/nitrous oxide groups for sex and tooth type were analyzed using the chi-square test or, if expected frequencies were <5, the Fisher exact test. Differences in age, initial pain scores, and degree of satisfaction were analyzed using the randomization test. Between-group differences in success were analyzed using a mixed model logistic regression with group and sex as the independent variables and tooth type and initial pain as the random variables. Comparisons were considered significant if P was <.05. With 102 subjects (50 in the ketorolac/nitrous oxide group and 52 in the saline/nitrous oxide group) and a nondirectional alpha risk of 0.05, the power of the chi-square test to detect a difference of AE30 percentage points in anesthetic success was 91%.
Results
Age, sex, initial pain, and tooth type of the patients are presented in Table 1 . There were no significant differences between the intranasal ketorolac/nitrous oxide and intranasal saline/nitrous oxide groups. All subjects in both groups reported initial moderate to severe pain. One hundred percent of the patients had subjective lip anesthesia with the IANBs. Side effects after intranasal administration were reported by 50% (25/50) of the subjects in the ketorolac/nitrous oxide group and 33% (17/52) in the saline/nitrous oxide group.
The regression analysis for anesthetic success is presented in Table 2 . The odds ratio for IANB success for the intranasal saline/ nitrous oxide group to the intranasal ketorolac/nitrous oxide group was 1.631 (95% confidence interval, .698-3.864). There was no significant difference between the 2 treatments (P = .2523). There were also no significant effects for sex (P = .3390) or sex by group interaction (P = .2878). The IANB success rate was 46% for the intranasal saline/nitrous oxide group and 54% for the intranasal ketorolac/nitrous oxide group. Both groups had the majority of the failures within the dentin. For the intranasal saline/nitrous oxide group, 61% (17/28) failed in the dentin, and 65% (15/23) failed for the intranasal ketorolac/nitrous oxide group.
The satisfaction ratings were 100% completely satisfied for the intranasal saline/nitrous oxide group and 4% moderately satisfied and 96% completely satisfied for the intranasal ketorolac/nitrous oxide. There was no significant difference (P = 1.000) between the 2 groups.
Discussion
There were no statistically significant differences for the effects of age, sex, initial presenting pain, and tooth type, so these variables were minimized between the 2 groups (Table 1) . Although there were a higher percentage of women than men in both groups, the results were similar to those found in an American Dental Association survey of endodontists (26) . The results showed that of the patients presenting for endodontic treatment, 59% were women and 41% were men, which is a similar distribution to the current study (approximately 64% were women). The mean initial pain ratings of 129 mm for the ketorolac/ nitrous oxide group and 130 mm for the saline/nitrous oxide group correlated to severe pain on the VAS. This pain is representative of patients with symptomatic irreversible pulpitis (3, 25, (27) (28) (29) (30) who present for emergency endodontic treatment.
There was no significant difference in the odds of IANB success for the intranasal ketorolac/nitrous oxide group versus the intranasal saline/nitrous oxide control group (P = .2523, Table 2 ). In patients with symptomatic irreversible pulpitis of mandibular posterior teeth, Stanley et al (3) found a statistically significant increase in success (50%) when using nitrous oxide compared with a 28% success rate using room air/oxygen (placebo). Our success rates using nitrous oxide (46% and 54%) were similar to those reported by Stanley et al (3) . We wanted to add the effect of ketorolac to try and increase the success of nitrous oxide. Unfortunately, intranasal ketorolac did not increase the success rate over nitrous oxide/oxygen alone. Clinically, the ketorolac and nitrous oxide would exert their effects individually. There would be no intranasal interaction. The results of the current study indicate that intranasal ketorolac does not increase the odds of success for the IANB injection.
Regarding the time involved for the administration of ketorolac, any preoperative administration of a drug (30-60 minutes before treatment) will extend the time of the appointment (ie, the drugs must be given time to work). This is a drawback to preemptive administration.
The results also make it difficult to justify the use of intranasal ketorolac because of its high cost ($$300 per bottle without insurance coverage). In medicine, intranasal ketorolac has been used successfully for the management of moderate to severe postoperative pain even though the cost is high (19, 20) . Usually, the cost in medicine is adjusted to a copay when the patient has insurance. This would also be true for this drug in dentistry.
There are a number of studies in endodontics using preemptive ketorolac to increase the success of the IANB in patients with irreversible pulpitis. Oral administration of 10-20 mg was used in the studies by Aggarwal et al (5), Jena and Shashirekha (6), Yadav et al (7) , and Saha et al (8) . A buccal infiltration of ketorolac was used by Aggarwal et al (9) and Akhlaghi et al (10) . All of the studies, except the one by Aggarwal et al (5) , showed significant increases in success (no or mild pain on access or instrumentation) with the use of ketorolac. Excluding the study by Saha et al (8) , only 20 to 25 patients per ketorolac group were evaluated in the previous studies, indicating they may have been underpowered. Saha et al (8) used 10 mg oral ketorolac in 42 patients and found a 76% success rate (no or mild pain on access or instrumentation), which is a very high success rate considering no supplemental injections were administered. Additionally, the Heft-Parker VAS initial presenting pain was 86 mm in the Saha et al (9) study compared with the current study ratings of 129-130 mm presenting pain levels. Perhaps sampling a population group with lower initial pain may have resulted in a higher success rate than the current study. Aggarwal et al (31) found a higher success rate for patients with irreversible pulpitis when presenting with low preoperative pain.
Intranasal ketorolac seemed to be well tolerated by the patients with only a few minor side effects. The most common complaints were burning, tingling, or an itching sensation after administration. These symptoms were reported by approximately 50% (25/50) of the patients but were transient, lasting only a few minutes. According to the manufacturer's website (23) , these adverse effects occur in #2% of patients and at a rate twice that of placebo. In the placebo group, 33% (17/52) of patients reported a burning or itching sensation, bad taste, or strange smell after administration of the saline spray. As in the treatment group, these side effects lasted only a few minutes.
Despite the findings of the current study that most patients experienced moderate to severe pain during endodontic treatment, the majority of patients in both groups were moderately to completely satisfied with their experience. Patient satisfaction may be related to the chairside manner of the endodontist or satisfaction with the emergency procedure in the hope that his or her discomfort will be resolved. Other studies have shown that patients were moderately or completely satisfied with endodontic treatment for symptomatic irreversible pulpitis even though moderate to severe pain was experienced (3, 25, (27) (28) (29) (30) .
In conclusion, premedication with intranasal ketorolac did not significantly increase the success of the IANB over the use of nitrous oxide/oxygen alone. The 46% and 54% success rates support previous findings that the administration of nitrous oxide/oxygen increases the success of the IANB in patients diagnosed with symptomatic irreversible pulpitis. Supplemental anesthesia will still be needed to achieve adequate pulpal anesthesia. 
